impact factor, citescore

Full Papers


Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study

1, 2, 3, 4, 5, 6, 7, 8


  1. Guys Hospital and St Thomas NHS Trust, London, UK.
  2. Griffith University, Brisbane, Australia.
  3. Hospital de Sant Joan Despí Moisès Broggi, Spain.
  4. Section of Rheumatology, University of Santo Tomas Hospital, Manila, Philippines.
  5. Novartis Pharma AG, Basel, Switzerland.
  6. Novartis Pharma AG, Basel, Switzerland.
  7. Novartis Farmaceutica SA, Barcelona, Spain.
  8. Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA.

2023 Vol.41, N°3
PI 0589, PF 0596
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 35916290 [PubMed]

Received: 01/02/2022
Accepted : 02/05/2022
In Press: 28/07/2022
Published: 23/03/2023


Dactylitis is an important clinical domain of psoriatic arthritis (PsA) associated with significant burden of disease and impaired function. Post-hoc analysis of the FUTURE 5 study was performed to evaluate the efficacy of secukinumab in patients with dactylitis at baseline over 2 years.
Randomised patients received secukinumab 300mg with loading dose (LD)/150mg LD/150mg without loading dose/placebo. Assessment of dactylitis was based on Leeds Dactylitis Index. Exploratory analyses included resolution of dactylitis based on severity, time to first resolution of dactylitis (Kaplan-Meier estimate) and resolution of dactylitis (heatmap analysis). Clinical efficacy outcomes, composite domains of disease activity, health-related quality of life (HRQoL) and radiographic progression using van der Heijde-modified total Sharp score were assessed in patients with/without dactylitis at baseline.
Overall, 389/996 (39%) patients presented with dactylitis at baseline, had more active clinical disease and greater disease activity than those without dactylitis at baseline. Resolution of dactylitis was observed across all treatment groups at Week 104. Improvement in joints, enthesitis, skin psoriasis, nail outcomes, physical function and HRQoL were sustained over 2 years in patients with dactylitis at baseline. With secukinumab treatment, >80% of patients did not show structural radiographic progression. The proportion of non-structural radiographic progressors were comparable across patients with/without dactylitis at baseline with secukinumab treatment over 2 years.
Patients with dactylitis at baseline were associated with higher burden of disease. Secukinumab provided sustained improvements across all clinical outcomes, QoL and inhibition of radiographic progression in PsA patients with dactylitis at baseline over 2 years.


Rheumatology Article

Rheumatology Addendum